SCHEMBL10697906

SCHEMBL10697906

CN1CCC2=CC=CCC2CC1

nearest known ligand 0.34

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
QDPR P09417 2/20 0.34
PLG P00747 1/20 0.33
DRD2 P14416 1/20 0.31
DRD1 P21728 1/20 0.31
DRD5 P21918 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3168555 0.84 QDPR (0.32) QDPRPLG
SCHEMBL13262405 0.80 QDPR (0.35) QDPRPLGDRD2DRD1DRD5
SCHEMBL20908872 0.77 QDPR (0.38) QDPRPLG
SCHEMBL4754795 0.76
SCHEMBL22038 0.72
SCHEMBL121612 0.71
Lithium SCHEMBL31113350 0.71
SCHEMBL28135379 0.71
SCHEMBL9831254 0.71
SCHEMBL28250424 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0278165-A2 Use of 3-benzazepines in the treatment of benign prostatic hypertrophy SMITHKLINE BEECHAM CORPORATION (US) 1988-08-17 EP disclosed